BIO-TECHNE Corp Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability
BIO-TECHNE Corp (TECH) reported Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability of $36.50 million for the 12-month period ending 2018-06-30, per its 10-K filed 2020-08-26.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability · last filed 2020-08-26
- BIO-TECHNE Corp income tax expense (benefit), continuing operations, adjustment of deferred tax (asset) liability for fiscal 2018 was $36.50M.
| Period end | Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability 6 month | Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability 12 month | Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability 12 month as first filed |
|---|---|---|---|
| 2018-06-30 | $36.50M 10-K · filed 2020-08-26 | -$36.50M 10-K · filed 2018-08-27 | |
| 2017-12-31 | -$37.00M 10-Q · filed 2018-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |